Jon Holman's Contact Details

Jon Holman's Company Details

Inmedix Inc

N/A, N/A, US • 5 - 9 Employees
BioTech/Drugs

Inmedix brings an essential new diagnostic, a new cloud platform and a new strategy to transform medicine, beginning with autoimmune disease .Next-generation Inmedix heart rate variability (HRV), the Inmedix Cloud diagnostics platform and its concept of Immuno-autonomics are the essence of applied transitional medicine to understand why patients respond differently to the same treatment.For autoimmune diseases like rheumatoid arthritis (RA), lupus (SLE) and multiple sclerosis (MS), the conundrum points to stress - traditionally thought of as a 'soft' science. But now through innovative, international research and undaunted clinical validation, this soft science is becoming increasingly hardened into its distinctive and actionable biologyThe autonomic nervous system, or ANS, within the brain modulates stress to enhance survival. Adrenaline (epinephrine) helps one escape the tiger to survive, but it also drives immune aggression. For an autoimmune disease, stress result in disastrous consequences for patients. In fact, 97% of UK patients with RA claimed in 2019 that stress caused disease flares.There is always a cause (or causes) for either treatment benefit and failure. Stress and immuno-autonomics appear to be an important target to understand why patients with autoimmune diseases respond differently to the same treatment. And, what you do not measure, you cannot manage. ANS stress state may be the most overlooked element of precision, personalized medicine. The trick is to measure ANS state accurately - something routinely and sadly taken for granted. Inmedix offers the precision medicine has been waiting for.See our new video at www.inmedix.com explaining immuno-autonomics.